Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 2 Seabreeze STAT Asthma study to evaluate the safety and efficacy of rademikibart for treating acute exacerbations in asthma. This study, which is expected to report topline data in the first half of 2026, aims to establish rademikibart as a potentially groundbreaking biologic treatment for patients experiencing acute asthma exacerbations. Following positive results from a previous global Phase 2 trial, rademikibart has demonstrated the ability to rapidly improve lung function within 24 hours and provide sustained improvements over 24 weeks. The company is also set to begin a similarly-designed Phase 2 study for COPD patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.